LTS Lohmann Therapie-Systeme AG
LTS Lohmann Therapie-Systeme AG, commonly referred to as LTS, is a leading global player in the pharmaceutical and medical device industry, headquartered in Andernach, Germany. Founded in 1981, the company has established itself as a pioneer in transdermal drug delivery systems, offering innovative solutions that enhance patient compliance and therapeutic efficacy. With a strong presence in Europe, North America, and Asia, LTS focuses on the development and manufacturing of advanced drug delivery technologies, including patches and films. Their unique approach combines cutting-edge research with state-of-the-art production capabilities, ensuring high-quality products tailored to meet diverse medical needs. Recognised for its commitment to excellence, LTS has achieved significant milestones, solidifying its market position as a trusted partner for pharmaceutical companies worldwide.
DitchCarbon Score
How does LTS Lohmann Therapie-Systeme AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
LTS Lohmann Therapie-Systeme AG's score of 15 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
LTS Lohmann Therapie-Systeme AG's reported carbon emissions
LTS Lohmann Therapie-Systeme AG, headquartered in Germany, has made significant commitments towards achieving net-zero carbon emissions by 2050. Although specific emissions data for the most recent year is not available, the company is actively engaged in climate initiatives and has committed to the Science Based Targets initiative (SBTi) for all scopes of emissions. Starting from 2023, LTS Lohmann has pledged to implement strategies aimed at reducing its carbon footprint across all operations. The company is a member of the BA1.5 initiative, which underscores its commitment to align with climate science and limit global warming to 1.5 degrees Celsius. LTS Lohmann's long-term climate strategy reflects a proactive approach to sustainability within the pharmaceuticals, biotechnology, and life sciences sector. By setting a net-zero target, the company aims to contribute positively to global climate goals while enhancing its operational efficiency and resilience.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
LTS Lohmann Therapie-Systeme AG is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
